Anesth Pain Med.  2023 Apr;18(2):114-122. 10.17085/apm.23041.

What we need to know and do on sugammadex usage in pregnant and lactating women and those on hormonal contraceptives

• Do W
• Cho AR

• KMID: 2543652
• DOI: http://doi.org/10.17085/apm.23041

Abstract

Sugammadex is a chemically modified γ-cyclodextrin that is used as a selective reversal agent for steroidal neuromuscular blockade. The use of sugammadex has greatly increased globally; however, little is known about its potential adverse effects in pregnant and lactating women or those using hormonal contraceptives. There are three important theoretical assumptions. Firstly, pregnancy-related physiological changes involve most organs and affect the pharmacokinetic profiles of medications. Considering the physiological changes in pregnant women and the pharmacokinetic properties of sugammadex, alterations in the dosage and safety profiles of sugammadex may occur during pregnancy. Secondly, very large and polarized sugammadex molecules are expected to have limited placental transfer to the fetus and excretion into breast milk. Finally, sugammadex can bind to steroidal neuromuscular blocking agents as well as other substances with similar structures, such as progesterone. As a result of using sugammadex, progesterone levels can be reduced, causing adverse effects such as early pregnancy cessation and failure of hormonal contraceptives. This narrative review aims to demonstrate the correlations between sugammadex and pregnancy, lactation, and reproductive potential based on previously published preclinical and clinical studies. This will bridge the gap between theoretical assumptions and currently unknown clinical facts. Moreover, this review highlights what anesthesia providers should be aware of and what actions to take while administering sugammadex to such patients.

Keyword

Hormonal contraceptives; Lactation; Pregnancy; Sugammadex

Reference

1. Hristovska AM, Duch P, Allingstrup M, Afshari A. Efficacy and safety of sugammadex versus neostigmine in reversing neuromuscular blockade in adults. Cochrane Database Syst Rev. 2017; 8:CD012763.

2. Abad-Gurumeta A, Ripollés-Melchor J, Casans-Francés R, Espinosa A, Martínez-Hurtado E, Fernández-Pérez C, et al. Evidence Anaesthesia Review Group. A systematic review of sugammadex vs neostigmine for reversal of neuromuscular blockade. Anaesthesia. 2015; 70:1441–52.

3. O'Reilly-Shah VN, Wolf FA, Jabaley CS, Lynde GC. Using a worldwide in-app survey to explore sugammadex usage patterns: a prospective observational study. Br J Anaesth. 2017; 119:333–5.

4. Mylan Ireland. Sugammadex Mylan. European Medicines Agency [Internet]. 2021 Nov 22 [updated 2022 Oct 3; cited 2023 Mar 23]. Available from https://www.ema.europa.eu/en/medicines/human/EPAR/sugammadex-mylan.

5. Sugammadex. PharmaCompass [Internet]. 2023 [cited 2023 Mar 23]. Available from https://www.pharmacompass.com/patent-expiry-expiration/sugammadex.

6. Nag K, Singh DR, Shetti AN, Kumar H, Sivashanmugam T, Parthasarathy S. Sugammadex: a revolutionary drug in neuromuscular pharmacology. Anesth Essays Res. 2013; 7:302–6.

7. Richardson MG, Raymond BL. Sugammadex administration in pregnant women and in women of reproductive potential: a narrative review. Anesth Analg. 2020; 130:1628–37.

8. Society for Obstetric Anesthesia and Perinatology. Statement on Sugammadex during pregnancy and lactation. Society for Obstetric Anesthesia and Perinatology [Internet]. 2019 Apr 22 [cited 2023 Mar 23]. Available from https://www.soap.org/assets/docs/SOAP_Statement_Sugammadex_During_Pregnancy_Lactation_APPROVED.pdf.

9. Bhatia P, Chhabra S. Physiological and anatomical changes of pregnancy: implications for anaesthesia. Indian J Anaesth. 2018; 62:651–7.

10. Costantine MM. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014; 5:65.

11. Pariente G, Leibson T, Carls A, Adams-Webber T, Ito S, Koren G. Pregnancy-associated changes in pharmacokinetics: a systematic review. PLoS Med. 2016; 13:e1002160.

12. McCormack SA, Best BM. Obstetric pharmacokinetic dosing studies are urgently needed. Front Pediatr. 2014; 2:9.

13. Gijsenbergh F, Ramael S, Houwing N, van Iersel T. First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology. 2005; 103:695–703.

14. Sorgenfrei IF, Norrild K, Larsen PB, Stensballe J, Ostergaard D, Prins ME, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: a dose-finding and safety study. Anesthesiology. 2006; 104:667–74.

15. Akha AS, Rosa J 3rd, Jahr JS, Li A, Kiai K. Sugammadex: cyclodextrins, development of selective binding agents, pharmacology, clinical development, and future directions. Anesthesiol Clin. 2010; 28:691–708. Erratum in: Anesthesiol Clin 2011; 29: 1.

16. Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015; 39:512–9.

17. Kovac AL. Sugammadex: the first selective binding reversal agent for neuromuscular block. J Clin Anesth. 2009; 21:444–53.

18. Singh S, Klumpner TT, Pancaro C, Rajala B, Kountanis JA. Sugammadex administration in pregnant women: a case series of maternal and fetal outcomes. A A Pract. 2021; 15:e01407.

19. Merck & Co., Inc. BRIDION®. Merck & Co., Inc. [Internet]. 2015 [updated 2022 Nov; cited 2023 Mar 22]. Available from https://www.merck.com/product/usa/pi_circulars/b/bridion/bridion_pi.pdf.

20. Palanca JM, Aguirre-Rueda D, Granell MV, Aldasoro M, Garcia A, Iradi A, et al. Sugammadex, a neuromuscular blockade reversal agent, causes neuronal apoptosis in primary cultures. Int J Med Sci. 2013; 10:1278–85.

21. Aldasoro M, Jorda A, Aldasoro C, Marchio P, Guerra-Ojeda S, Gimeno-Raga M, et al. Neuronal effects of Sugammadex in combination with Rocuronium or Vecuronium. Int J Med Sci. 2017; 14:224–30.

22. Creeley CE, Dikranian KT, Dissen GA, Back SA, Olney JW, Brambrink AM. Isoflurane-induced apoptosis of neurons and oligodendrocytes in the fetal rhesus macaque brain. Anesthesiology. 2014; 120:626–38.

23. Rappaport BA, Suresh S, Hertz S, Evers AS, Orser BA. Anesthetic neurotoxicity--clinical implications of animal models. N Engl J Med. 2015; 372:796–7.

24. Satomoto M, Sun Z, Adachi YU, Makita K. Sugammadex-enhanced neuronal apoptosis following neonatal sevoflurane exposure in mice. Anesthesiol Res Pract. 2016; 2016:9682703. Erratum in: Anesthesiol Res Pract. 2017; 2017: 1368514.

25. Et T, Topal A, Erol A, Tavlan A, Kılıçaslan A, Uzun ST. The effects of Sugammadex on progesterone levels in pregnant rats. Balkan Med J. 2015; 32:203–7.

26. Türk R, Kaya S, Dönmez İ, Özaydin İ, Merhan O, Yayla S, et al. The effect of Rocuronium and Sugammadex on progesterone levels in pregnant rabbits under general anesthesia. Kafkas Univ Vet Fak Derg. 2019; 25:179–84.

27. Ito S, Lee A. Drug excretion into breast milk--overview. Adv Drug Deliv Rev. 2003; 55:617–27.

28. Watson SE, Richardson AL, Lucas DN. Neuraxial and general anaesthesia for caesarean section. Best Pract Res Clin Anaesthesiol. 2022; 36:53–68.

29. Stourac P, Adamus M, Seidlova D, Pavlik T, Janku P, Krikava I, et al. Low-dose or high-dose Rocuronium reversed with Neostigmine or Sugammadex for cesarean delivery anesthesia: a randomized controlled noninferiority trial of time to tracheal intubation and extubation. Anesth Analg. 2016; 122:1536–45.

30. Williamson RM, Mallaiah S, Barclay P. Rocuronium and Sugammadex for rapid sequence induction of obstetric general anaesthesia. Acta Anaesthesiol Scand. 2011; 55:694–9.

31. Pühringer FK, Kristen P, Rex C. Sugammadex reversal of rocuronium-induced neuromuscular block in caesarean section patients: a series of seven cases. Br J Anaesth. 2010; 105:657–60.

32. Reale SC, Bauer ME, Klumpner TT, Aziz MF, Fields KG, Hurwitz R, et al. Multicenter Perioperative Outcomes Group Collaborators. Frequency and risk factors for difficult intubation in women undergoing general anesthesia for cesarean delivery: a multicenter retrospective cohort analysis. Anesthesiology. 2022; 136:697–708.

33. Odor PM, Bampoe S, Moonesinghe SR, Andrade J, Pandit JJ, Lucas DN. General anaesthetic and airway management practice for obstetric surgery in England: a prospective, multicentre observational study. Anaesthesia. 2021; 76:460–71.

34. Kheterpal S, Healy D, Aziz MF, Shanks AM, Freundlich RE, Linton F, et al. Multicenter Perioperative Outcomes Group (MPOG) Perioperative Clinical Research Committee. Incidence, predictors, and outcome of difficult mask ventilation combined with difficult laryngoscopy: a report from the multicenter perioperative outcomes group. Anesthesiology. 2013; 119:1360–9.

35. Schroeder RA, Pollard R, Dhakal I, Cooter M, Aronson S, Grichnik K, et al. Temporal trends in difficult and failed tracheal intubation in a regional community anesthetic practice. Anesthesiology. 2018; 128:502–10.

36. Mushambi MC, Kinsella SM, Popat M, Swales H, Ramaswamy KK, Winton AL, et al. Obstetric Anaesthetists' Association and Difficult Airway Society guidelines for the management of difficult and failed tracheal intubation in obstetrics. Anaesthesia. 2015; 70:1286–306.

37. Munro A, McKeen D, Coolen J. Maternal respiratory distress and successful reversal with Sugammadex during intrauterine transfusion with fetal paralysis. Int J Obstet Anesth. 2019; 39:129–31.

38. Torres SM, Duarte DF, Glória AS, Reis C, Moreira JF, Cunha S, et al. Sugammadex administration in pregnant patients undergoing non-obstetric surgery: a case series. Braz J Anesthesiol. 2022; 72:525–8.

39. Noguchi S, Iwasaki H, Shiko Y, Kawasaki Y, Ishida Y, Shinomiya S, et al. Fetal outcomes with and without the use of Sugammadex in pregnant patients undergoing non-obstetric surgery: a multicenter retrospective study. Int J Obstet Anesth. 2023; 53:103620.

40. Karahan MA, Büyükfırat E, Binici O, Uyanıkoğlu H, Incebıyık A, Asoğlu M, et al. The effects of Rocuronium-sugammadex on fetomaternal outcomes in pregnancy undergoing electroconvulsive therapy: a retrospective case series and literature review. Cureus. 2019; 11:e4820.

41. Devoy T, Hunter M, Smith NA. A prospective observational study of the effects of Sugammadex on peri-operative oestrogen and progesterone levels in women who take hormonal contraception. Anaesthesia. 2023; 78:180–7.

42. Gunduz Gul G, Ozer AB, Demirel I, Aksu A, Erhan OL. The effect of sugammadex on steroid hormones: a randomized clinical study. J Clin Anesth. 2016; 34:62–7.

43. Lazorwitz A, Dindinger E, Aguirre N, Sheeder J. Pre- and post-operative counseling for women on hormonal contraceptives receiving Sugammadex at an academic hospital. J Anesth. 2020; 34:294–7.

44. Dwan RL, Raymond BL, Richardson MG. Unanticipated consequences of switching to Sugammadex: anesthesia provider survey on the hormone contraceptive drug interaction. Anesth Analg. 2021; 133:958–66.

45. Passi NN, Mutebi M, Tan M, Oliver CM. Contraceptive failure and Sugammadex administration: a single centre survey and audit of professional knowledge and practice. Br J Anaesth. 2023; 130:e412–4.

46. Liverpool Women's National Health Service (NHS) Foundation Trust. Anaesthetics leaflets. Liverpool Women's NHS Foundation Trust [Internet]. 2020 [cited 2023 Mar 29]. Available from https://www.liverpoolwomens.nhs.uk/patients/patient-information-leaflets/anaesthetics/.

47. University College London Hospitals. University college hospital: Contraceptive advice for patients who have received Sugammeadex. National Health Service [Internet]. 2022 Jul [cited 2023 Mar 29]. Available from https://www.uclh.nhs.uk/application/files/9716/5815/8160/Sugammeadex_Contraceptive_advice.pdf.

48. Sugammadex. In: Drugs and lactation database (LactMed®). Bethesda (MD), National Institute of Child Health and Human Development. 2020.

49. Mitchell J, Jones W, Winkley E, Kinsella SM. Guideline on anaesthesia and sedation in breastfeeding women 2020: guideline from the Association of Anaesthetists. Anaesthesia. 2020; 75:1482–93.

50. World Health Organization (WHO). Breastfeeding. WHO [Internet]. [cited 2023 Mar 23]. Available from https://www.who.int/health-topics/breastfeeding.

51. Newton ER, Hale TW. Drugs in breast milk. Clin Obstet Gynecol. 2015; 58:868–84.